3,300.00

Content Details
Information on this page was last modified on : 2019/08/10 6:00:41 PM
, This drug requires a valid prescription from PMDC registered health practitioner.
Manufactured by
Contains

Jilifen Injection contains Filgrastim | belongs to Recombinant G-CSF (Recombinant human granulocyte-colony stimulating factor)

Product SKUpg_11822_16394
Drug Strength
Pack size

Side effects

Major & minor side effects for Jilifen Injection 300 mcg 1 Vialx1.2 mL

  • Stomach pain severe
  • Hair loss severe
  • Constipation severe
  • Nausea or Vomiting severe
  • Fever and chills severe
  • Bone pain severe
  • Loss of appetite
  • Weight loss
  • Swelling or inflammation of mouth

Uses of Jilifen Injection 300 mcg 1 Vialx1.2 mL

What is it prescribed for?

  • Neutropenia caused by chemotherapy

    Jilifen Injection 300 mcg 1 Vialx1.2 mL is used to reduce the incidence of infection in patients receiving myelosuppressive anti-cancer drugs.

  • Bone Marrow Transplantation

    This medicine is used to treat febrile neutropenia, the fever caused due to decreased neutrophil count in patients receiving chemotherapy followed by bone marrow transplantation.

  • Peripheral Progenitor Cell Transplantation

    This medicine is used before the procedure of leukapheresis to mobilize the autologus hematopoietic progenitor cells into the peripheral blood for collection.

  • Chronic Neutropenia

    Jilifen Injection 300 mcg 1 Vialx1.2 mL is used to reduce the incidence of infection, fever, and oropharyngeal ulcers in patients with chronic neutropenia.

  • Neutropenia caused by radiation

    Jilifen Injection 300 mcg 1 Vialx1.2 mL is used to increase the survival rate in patients who have received high doses of myelosuppressive radiation.

Concerns

Frequently asked questions

  • Onset of action

    The amount of time required for this medicine to show its effect is 1 to 3 days.

  • Duration of Effect

    The amount of time for which this medicine remains active in the body is not clinically established.

  • Safe with Alchohol?

    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

  • Is it habit forming?

    No habit forming tendency has been reported.

  • Usage in pregnancy?

    This medicine is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before taking this medicine.

  • Usage while breast-feeding?

    This medicine is not recommended for use in breastfeeding women unless necessary. The risks and benefits should be discussed with the doctor before taking this medicine.

When not to use?

  • Allergy

    This medicine is not recommended for use in patients with a known allergy to Jilifen Injection 300 mcg 1 Vialx1.2 mL and peg Jilifen Injection 300 mcg 1 Vialx1.2 mL products.

Warnings

Warnings for special population
  • Pregnancy

    This medicine is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before taking this medicine.

  • Breast-feeding

    This medicine is not recommended for use in breastfeeding women unless necessary. The risks and benefits should be discussed with the doctor before taking this medicine.

Warnings

Warnings for special population
  • Splenic Rupture

    This medicine should be used with caution due to the increased risk of splenic rupture. Patients having abdominal and/or shoulder tip pain while taking this medicine should consult the doctor immediately. Your doctor may advise you to stop the medicine based on your clinical condition.

  • Acute Respiratory Distress Syndrome (ARDS)

    This medicine has been shown to cause Acute respiratory distress syndrome in rare cases. Discuss the risks and benefits with your doctor before taking this medicine. Report any symptoms of fever or respiratory distress to the doctor on priority. Replacement with a suitable alternative might be required based on the clinical condition.

  • Sickle cell crisis

    This medicine not recommended for use in patients with a known history of sickle cell disease due to the increased risk of serious and life threatening reactions. Discuss the risks and benefits with your doctor before taking this medicine. Replacement with a suitable alternative might be required based on the clinical condition.

Dosage

  • Missed Dose

    If a dose of Jilifen Injection 300 mcg 1 Vialx1.2 mL is missed, take the dose as soon as you remember. If it is almost the time for the next dose, skip the missed dose and take the next dose. Do not double the dose to make up for the missed one.

  • Overdose

    Seek emergency medical treatment or contact the doctor in case of an overdose.

Interactions

Interaction with Medicines
  • Cisplatin moderate
  • Fluorouracil moderate
  • Doxorubicin moderate
Disease interactions
  • severe

    This medicine should be used with caution in patients with Renal dysfunction due to the increased risk of glomerulonephritis. Report to the doctor any symptoms such as swelling of ankles and face, blood in the urine, dark colored urine, or decreased urine output immediately. An alternative treatment option should be considered based on the clinical condition of the patient.

  • severe

    This medicine should be used with caution in patients with Myeloid tumors due to the increased risk of tumor growth. Report to the doctor all your medical conditions before taking this medicine.

  • severe

    This medicine should be used with caution in patients with Leukocytosis due to the increased risk of excessive white blood cell count. Appropriate dose adjustments or replacement with an alternative medicine should be done under your doctor's supervision.

General Instructions

Do not use Jilifen Injection 300 mcg 1 Vialx1.2 mL for any conditions other than those specified by the doctor. Report to the doctor all your medical conditions and current medicines before taking this medication. Report any undesired effects or lack of improvement to the doctor on priority.

Other details

  • Usage does not depend on food timings
  • To be taken as instructed by doctor
  • Does not cause sleepiness

How it works

This medicine works by stimulating the production of white blood cells and thus helps to fight against infections.

References

How to use Jilifen Injection 300 mcg 1 Vialx1.2 mL

May be administered undiluted by SC or IVP administration. May also be administered by IV infusion over 15-60 min in D5W. For SC dose larger than 1 mL, divide and give in more than one site.
Reconstitution: Filgrastim may be diluted in dextrose 5% in water to a concentration gt;15 mcg/mL for IV Infusion administration. Minimum concentration is 15 mcg/mL. Concentrations lt;15 mcg/mL require addition of albumin (1 mL of 5%)to the bag to prevent absorption to plastics/PVC.
Compatibility: Standard diluent: gt;375 mcg/25 mL D5W. Stable in D5W; incompatible with NS.
Stability: Store at 2°C-8°C (36°F-46°F). Avoid shaking prior to injection, filgrastim may be allowed to reach room temperature for a maximum of 24 hours. Any vial or prefilled syringe left at room temperature for more than 24 hours should be discarded.

UNLICENSED USE
Children: Neonatal neutropenia: SC injection. Neonate 10 mcg/kg daily, discontinue if white cell count exceeds 50 6 109/litre.
Glycogen storage disease type 1b: SC injection. 5 mcg/kg daily, adjusted as necessary.

what are the adverse effects of Jilifen Injection 300 mcg 1 Vialx1.2 mL

Anorexia, headache, asthaenia, fever, musculoskeletal pain, bone pain, rash, alopecia, thrombocytopenia, leukocytosis. Chest pain, interstitial pneumonia, cutaneous vasculitis, acute febrile neutrophilic dermatitis. Splenic enlargement, hepatomegaly, transient hypotension, epistaxis, urinary abnormalities, osteoporosis, exacerbation of rheumatoid arthritis, anaemia, transient decrease in blood glucose, pseudogout and raised uric acid. infection, muscle spasm, dizziness, insomnia, oropharyngeal pain, cough, dyspnoea, GI upset, fatigue, pyrexia, mucosal inflammation, hypertension, haemoptysis, dysuria, chest pain, hypoglycaemia, hypoaesthesia, paraesthesia, haematuria, peripheral oedema, cutaneous vasculitis, glomerulonephritis, lactic dehydrogenase and LFTs, inj site reactions. Reports of aortitis.

What is the dose of Jilifen Injection 300 mcg 1 Vialx1.2 mL

Myelosuppressive Chemotherapy: Adults: Initial: 5 mcg/kg/day IV/SC.
BMT Cancer: Adults: Initial: 10 mcg/kg/day IV/SC.
Congenital Neutropenia: Adults: Initial: 6 mcg/kg SC twice daily.
Idiopathic/Cyclic Neutropenia: Adults: Initial: 5 mcg/kg SC once daily. Maintenance dose for above based on neutrophil count.
Peripheral Blood Progenitor Cell Collection: Adults: Initial: 10 mcg/kg/day SC four day before & for 6-7 day with leukapheresis on day 5th, day 6th & day 7th.Children: Cytotoxic-induced neutropenia: Preferably SC injection or by IV infusion (over 30 minutes). 1 mth-18 yr, 5 mcg/kg daily started not less than 24 hr after cytotoxic chemotherapy, continued until neutrophil count in normal range, usually for up to 14 days (up to 38 days in acute myeloid leukaemia).
Myeloablative therapy followed by bone-marrow transplantation: IV infusion over 30 minutes or over 24 hr or by SC infusion over 24 hr. 1 mth-18 yr, 10 mcg/kg daily, started not less than 24 hr following cytotoxic chemotherapy (and within 24 hr of bone-marrow infusion), then adjusted according to absolute neutrophil count.
Mobilisation of peripheral blood progenitor cells for autologous infusion, used alone: SC injection or SC infusion over 24 hr. 1 mth-18 yr, 10 mcg/kg daily for 5-7 days.
Mobilisation of peripheral blood progenitor cells for autologous infusion following adjunctive myelosuppressive chemotherapy (to improve yield): SC injection. 1 mth-18 yr, 5 mcg/kg daily, started the day after completion of chemotherapy and continued until neutrophil count in normal range; for timing of leucopheresis consult product literature.
Mobilisation of peripheral blood progenitor cells in normal donors for allogeneic infusion: SC injection. Over 16 yr, 10 mcg/kg daily for 4-5 days; for timing of leucopheresis consult product literature.
Severe chronic neutropenia: SC injection. 1 mth-18 yr in severe congenital neutropenia, initially 12 mcg/kg daily in single or divided doses (initially 5 mcg/kg daily in idiopathic or cyclic neutropenia), adjusted according to response (consult product literature).
Persistent neutropenia in HIV infection: SC injection. 1 mth-18 yr, initially 1 mcg/kg daily, increased as necessary until absolute neutrophil count in normal range (usual max 4 mcg/kg daily), then adjusted to maintain absolute neutrophil count in normal range (consult product literature).

One of the following licensed pharmacy from the nearest location will deliver Jilifen Injection 300 mcg 1 Vialx1.2 mL. The details of the licensed pharmacy shall be shared once you request the drugs and the respective pharmacy accepts the your request based on valid prescription and availability.

Want to share this information?
Facebook
Twitter
LinkedIn
Something doesn't feel right ?

Reviews

There are no reviews yet.

Be the first to review “Jilifen Injection 300 mcg 1 Vialx1.2 mL”

Questions and answers of the customers

There are no questions yet. Be the first to ask a question about this product.

Send me a notification for each new answer.
میڈیکل اسٹور مالکان کے لئے ھول سیل ریٹس پرفری ڈیلوری